GLP-1 medication access online for Lowell, Massachusetts
Company statements checked between September 13, 2026 and September 23, 2026: 3 covered companies — GoodRx Care, Mochi Health and OrderlyMeds — advertise online GLP-1 medication access for patients in Massachusetts, including Lowell. Confirm eligibility and total charges with the provider.
Browse online GLP-1 medication access programs advertised for patients in Lowell, Massachusetts, with state-level access evidence.
Inside Telehealth Editorial · Updated
At a glance
| Company | On this page | Lowest listed monthly figure | Checked | Official site |
|---|---|---|---|---|
| GoodRx Care | Wegovy pen · Wegovy HD · Wegovy tablet · Zepbound KwikPen | $188/mo partial monthly subtotal, Wegovy tablet | Official site ↗ | |
| Mochi Health | Compounded semaglutide · Compounded tirzepatide | $139/mo partial monthly subtotal, Compounded semaglutide | Official site ↗ | |
| OrderlyMeds | Wegovy · Zepbound | $1,498/mo advertised monthly bundle, Zepbound | Official site ↗ |
Health context in Lowell
GLP-1 medication access programs are marketed for weight management and, for some products, type 2 diabetes. These Lowell figures give local context only. Among the 5 Massachusetts cities in this research set, Lowell has the lowest estimate for routine checkup in the past year among adults (78%).
| Measure | Lowell | 95% range | Among the 5 Massachusetts cities in this research set | Year |
|---|---|---|---|---|
| Obesity among adults | 27.7% | 24.3–31.4% | third-highest | 2023 |
| Diagnosed diabetes among adults | 11.2% | 10–12.4% | third-highest | 2023 |
| High blood pressure among adults | 29.8% | 27.6–32.2% | third-highest | 2023 |
| Lack of health insurance among adults aged 18–64 | 8.2% | 7.2–9.4% | third-highest | 2023 |
| Routine checkup in the past year among adults | 78% | 75.6–80.4% | lowest | 2023 |
Source: CDC PLACES, 2025 release — model-based estimates from the Behavioral Risk Factor Surveillance System for Census place geography (total population 115,554); each measure is an estimate for adults. These describe the city's adults as a group; they do not indicate whether any person is eligible for, or should use, a treatment listed here.
This GLP-1 medication access page is the Lowell entry point to the Massachusetts statewide online listing, not evidence of an office, pharmacy or clinician in Lowell. Each company below appears because its named products have their own Massachusetts evidence; the heading does not extend coverage to every medicine in the category, and branded and compounded products are listed separately.
Use the Massachusetts guide to compare the listed programs, their separate prices and their billing and cancellation terms before choosing which offer to ask a company about.
These are online services advertised for patients in Massachusetts, listed alphabetically. They are not verified offices, pharmacies or clinicians located in Lowell, and a listing is not a prescription, appointment or coverage guarantee. Read the Massachusetts GLP-1 medication access guide for product details, charges and limitations.
Selected providers
GoodRx Care
GoodRx Care Direct, a cash-pay membership through which GoodRx advertises separately priced branded semaglutide and tirzepatide products.
Wegovy pen (pen): 0.25 or 0.5 mg, first two fills — $238/mo · after the first two fills — $388/mo
Wegovy HD (pen): 7.2 mg — $438/mo
Wegovy tablet (oral tablet): 1.5 mg — $188/mo · 4 mg — $238/mo · higher doses, from — $338/mo
Zepbound KwikPen (pen): introductory KwikPen strength (page labels it 10 mg) — $338/mo
- Wegovy pen — pen: state evidence checked · Availability source · Full evidence notes
- Wegovy HD — pen: state evidence checked · Availability source · Full evidence notes
- Wegovy tablet — oral tablet: state evidence checked · Availability source · Full evidence notes
- Zepbound KwikPen — pen: state evidence checked · Availability source · Full evidence notes
Mochi Health
Paid Mochi membership with separately billed compounded semaglutide or tirzepatide orders, if prescribed.
Compounded semaglutide (injection): 0.22 mg/week — $139/mo · 0.44 mg/week — $149/mo · 0.88 mg/week — $161/mo · 1.5 mg/week — $171/mo · 2.21 mg/week — $175/mo · 2.67 mg/week — $178/mo
Compounded tirzepatide (injection): 2.2 mg/week — $169/mo · 4.4 mg/week — $198/mo · 6.6 mg/week — $223/mo · 8.8 mg/week — $253/mo · 11.24 mg/week — $263/mo · 13.2 mg/week — $273/mo · 16.6 mg/week — $278/mo
- Compounded semaglutide — injection: state evidence checked · Availability source · Full evidence notes
- Compounded tirzepatide — injection: state evidence checked · Availability source · Full evidence notes
OrderlyMeds
OrderlyMeds branded Wegovy and Zepbound injection plans, each priced separately.
Wegovy (pen): .25mg, .5mg and 1mg (listed doses) — $1,839/mo
Zepbound (pen): 2.5 mg to 15 mg (advertised range) — $1,498/mo
- Wegovy — pen: state evidence checked · Availability source · Full evidence notes
- Zepbound — pen: state evidence checked · Availability source · Full evidence notes
Health center sites with Lowell addresses
If you want an in-person visit, HRSA-listed health center sites with Lowell postal addresses include:
- LCHC Consolidated Site (Lowell Community Health Center, Inc.) — 161 Jackson St, Lowell, MA 01852 · 978-937-9700
From the HRSA health center directory (data retrieved ), listed alphabetically by organization and matched by postal address, not city boundaries; the list includes health center look-alikes, which do not receive Health Center Program funding. Not a ranking or recommendation. Call to confirm services, costs and whether a site can help with the programs on this page.
More listings
Other medications for Lowell: Semaglutide · Tirzepatide
GLP-1 medication access in other Massachusetts cities: Boston · Cambridge · Springfield · Worcester
Before requesting a prescription
Confirm the named product is offered where you will be during the visit, check eligibility, total charges and any supply commitment, and ask what happens if you need in-person care. This listing does not assess which treatment is right for you.